In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Castle Biosciences (CSTL – Research Report), with a price target of $33.00. The company’s shares closed last Friday at $21.00.
According to TipRanks, Ji Nam is an analyst with an average return of -1.8% and a 47.80% success rate. Ji Nam covers the Healthcare sector, focusing on stocks such as Guardant Health, Castle Biosciences, and Olink Holding.
Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $31.71.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $29.59 and a one-year low of $9.26. Currently, Castle Biosciences has an average volume of 270.4K.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSTL in relation to earlier this year. Earlier this month, Juvenal Tobin W, the CCO of CSTL bought 6,701.00 shares for a total of $19,381.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castle Biosciences (CSTL) Company Description:
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Read More on CSTL:
